Form 4: BeOne Medicines Grants Significant Equity Awards to SVP, General Counsel

BeOne Medicines Ltd. has granted its Senior Vice President and General Counsel, Lee Chan Henry, a substantial package of restricted share units and share options, aligning executive incentives with long-term company performance.

Summary

• Lee Chan Henry, SVP, General Counsel of BeOne Medicines Ltd. (ONC), acquired 46,878 Ordinary Shares in the form of restricted share units (RSUs) on June 10, 2025, at a price of $0.
• These RSUs represent securities underlying restricted share units, with 1/4th vesting on each anniversary of June 10, 2025, subject to continued service, and accelerated vesting upon certain termination events.
• Following this transaction, Lee Chan Henry beneficially owns 283,920 Ordinary Shares directly.
• Additionally, Mr. Henry acquired 88,244 share options (right to buy) on June 10, 2025, with an exercise price of $20.26 per share.
• These share options vest over a four-year period: 25% on the first anniversary of June 10, 2025, with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service.
• The options expire on June 09, 2035, and unvested securities are subject to accelerated vesting upon certain termination events.
• Each American Depositary Share (ADS) of BeOne Medicines represents 13 ordinary shares.

Sentiment

Score: 6

Explanation: The document reports a routine executive compensation event. It is generally positive as it aligns executive interests with shareholders and aids retention, but it does not indicate new operational achievements or significant financial performance changes.

Positives

• The equity grants align the interests of a key executive, Lee Chan Henry, with the long-term performance and shareholder value of BeOne Medicines Ltd.
• The vesting schedules for both RSUs and share options incentivize continued service and retention of a senior legal executive.
• Granting equity at a $0 price for RSUs and options at a specific exercise price is a common and effective method of executive compensation, promoting commitment without immediate cash outlay from the executive.

Negatives

• The issuance of new equity awards, particularly share options, can lead to potential future dilution for existing shareholders if the options are exercised, although this is a standard aspect of equity compensation plans.

Risks

• The vesting of both restricted share units and share options is subject to the executive's continued service, meaning the benefits are contingent on ongoing employment.
• While there are provisions for accelerated vesting upon certain termination events, the specific conditions and their implications are not fully detailed in this filing, which could introduce uncertainty.

Future Outlook

The grants of restricted share units and share options are structured with multi-year vesting schedules, indicating an expectation for the executive's continued service and contribution to the company's performance through at least June 2029 for RSUs and June 2029 for options (based on 4-year vesting from June 2025).

Management Comments

• The filing itself is a statement of changes in beneficial ownership by a member of management, Lee Chan Henry, SVP, General Counsel. It does not contain direct quotes or paraphrased statements from management, but rather reports on their equity transactions.

Industry Context

The granting of restricted stock units and share options to senior executives is a standard and widespread practice across various industries, particularly in publicly traded companies. This compensation structure is designed to align executive incentives with shareholder interests by tying a significant portion of their compensation to the company's stock performance and long-term value creation. It is a common tool for executive retention and motivation.

Comparison to Industry Standards

• The use of both restricted share units (RSUs) and share options as components of executive compensation is a common practice, comparable to compensation packages offered by many companies in the biotechnology and pharmaceutical sectors, such as Moderna, BioNTech, or Regeneron Pharmaceuticals, which frequently utilize similar equity-based incentives.
• The vesting schedule of 25% on the first anniversary and monthly thereafter for options, and 1/4th annually for RSUs over four years, is a typical structure for long-term incentive plans, aiming to retain executives over a multi-year period, similar to programs at companies like Pfizer or Johnson & Johnson.
• The exercise price of $20.26 for the options, while specific to BeOne Medicines, is a standard feature of options, typically set at the market price on the grant date, which is a common industry benchmark for 'at-the-money' options.

Corporate Governance

Related Party Transactions

• The acquisition of restricted share units and share options by Lee Chan Henry, a Senior Vice President and General Counsel of BeOne Medicines Ltd., constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: Potential future dilution if share options are exercised, but also benefit from increased executive alignment with long-term company performance and value creation.
• Employees: Retention of a key senior executive, which can contribute to stability and continuity in the company's legal and strategic functions.

Next Steps

• Continued vesting of the 46,878 restricted share units over the next four years, with 1/4th vesting annually from June 10, 2025.
• Continued vesting of the 88,244 share options over the next four years, with 25% vesting on June 10, 2026, and the remainder in 36 equal monthly installments thereafter.
• Potential exercise of share options by Lee Chan Henry prior to their expiration on June 09, 2035, subject to vesting and market conditions.

Key Dates

Keywords

SEC Form 4, BeOne Medicines, ONC, executive compensation, restricted share units, share options, insider transaction, equity grant, corporate governance, SVP General Counsel